ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 1 مورد

Key differences between TNF-alpha antagonists

Key differences between TNF-alpha antagonists
TNF-alpha antagonist Drug design Routes of administration Usual frequency of maintenance therapy* Therapeutic differences
Adalimumab and biosimilars to adalimumab Fully human anti-TNF-alpha monoclonal antibody Subcutaneous Every 2 weeks  
Certolizumab pegol Antigen-binding fragment (Fab') of a humanized monoclonal antibody coupled to polyethylene glycol Subcutaneous Every 2 to 4 weeks
  • Unlike other TNF-alpha antagonists, does not contain an Fc portion
  • Minimal transfer across the placenta during pregnancy
Etanercept and biosimilars to etanercept Soluble p75 TNF-alpha receptor fusion protein Subcutaneous Once weekly
  • Unlike other TNF-alpha antagonists, etanercept is generally not effective for treatment of inflammatory bowel disease, uveitis, or sarcoidosis
  • Anti-drug antibodies are generally non-neutralizing (ie, do not affect clinical response)
Golimumab Human anti-TNF-alpha monoclonal antibody Subcutaneous or intravenous

Every 4 weeks (subcutaneous)

or

Every 8 weeks (intravenous)		  
Infliximab and biosimilars to infliximab Chimeric (mouse/human) anti-TNF-alpha monoclonal antibody Subcutaneous (biosimilar) or intravenous

Every 2 weeks (subcutaneous)

or

Every 4 to 8 weeks (intravenous)		  
To be used with UpToDate content on TNF-alpha inhibitors.

TNF: tumor necrosis factor.

* Frequency may vary by therapeutic indication. Please refer to UpToDate content on specific disease topics.
Graphic 143697 Version 2.0